Journal article Open Access

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

Vincenzo Quagliariello; Margherita Passariello; Domenica Rea; Antonio Barbieri; Martina Iovine; Annamaria Bonelli; Antonietta Caronna; Gerardo Botti; Claudia De Lorenzo; Nicola Maurea


JSON-LD (schema.org) Export

{
  "description": "<p>Several strategies based on immune checkpoint inhibitors (ICIs) have been developed for cancer therapy, opening to advantages in cancer outcomes. However, several ICI-induced side effects have emerged in these patients, especially a rare but clinically significant cardiotoxicity with high rate of mortality. We studied the cytotoxic and pro-inflammatory properties of Ipilimumab and Nivolumab, the underlying pathways and cytokine storm involved. Methods: Co-cultures of human cardiomyocytes and lymphocytes were exposed to Ipilimumab or Nivolumab; cell viability and expression of leukotrienes, NLRP3, MyD88, and p65/NF-kB were performed. C57 mice were treated with Ipilimumab (15 mg/kg); analysis of fractional shortening, ejection fraction, radial and longitudinal strain were made before and after treatments through 2D-echocardiography. Expression of NLRP3, MyD88, p65/NF-kB, and 12 cytokines were analyzed in murine myocardium. Results: Nivolumab and Ipilimumab exert effective anticancer, but also significant cardiotoxic effects in co-cultures of lymphocytes and tumor or cardiac cells. Both ICIs increased NLRP3, MyD88, and p65/NF-kB expression compared to untreated cells, however, the most pro-inflammatory and cardiotoxic effects were seen after exposure to Ipilimumab. Mice treated with Ipilimumab showed a significant decrease in fractional shortening and radial strain with respect to untreated mice, coupled with a significant increase in myocardial expression of NLRP3, MyD88, and several interleukins. Conclusions: Nivolumab and Ipilimumab exert cytotoxic effects mediated by the NLRP3/IL-1&beta; and MyD88 pathways, leading to pro-inflammatory cytokine storm in heart tissue.</p>", 
  "license": "https://creativecommons.org/licenses/by/4.0/legalcode", 
  "creator": [
    {
      "affiliation": "Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Vincenzo Quagliariello"
    }, 
    {
      "affiliation": "CEINGE\u2014Biotecnologie Avanzate s.c.a.r.l.,", 
      "@type": "Person", 
      "name": "Margherita Passariello"
    }, 
    {
      "affiliation": "Animal Facility, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Domenica Rea"
    }, 
    {
      "affiliation": "Animal Facility, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Antonio Barbieri"
    }, 
    {
      "affiliation": "Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Martina Iovine"
    }, 
    {
      "affiliation": "Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Annamaria Bonelli"
    }, 
    {
      "affiliation": "Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Antonietta Caronna"
    }, 
    {
      "affiliation": "Scientific Direction, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Gerardo Botti"
    }, 
    {
      "affiliation": "Department of Molecular Medicine and Medical Biotechnology, University of Naples \"Federico II\"", 
      "@type": "Person", 
      "name": "Claudia De Lorenzo"
    }, 
    {
      "affiliation": "Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale", 
      "@type": "Person", 
      "name": "Nicola Maurea"
    }
  ], 
  "sameAs": [
    "https://doi.org/10.3390/jpm10040179"
  ], 
  "image": "https://zenodo.org/static/img/logos/zenodo-gradient-round.svg", 
  "datePublished": "2020-10-19", 
  "headline": "Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models", 
  "url": "https://zenodo.org/record/5152889", 
  "@context": "https://schema.org/", 
  "identifier": "https://doi.org/10.5281/zenodo.5152889", 
  "@id": "https://doi.org/10.5281/zenodo.5152889", 
  "@type": "ScholarlyArticle", 
  "name": "Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models"
}
25
36
views
downloads
All versions This version
Views 2525
Downloads 3636
Data volume 108.8 MB108.8 MB
Unique views 2323
Unique downloads 2727

Share

Cite as